Regeneron Pharmaceuticals Inc. buy Sanford C. Bernstein
Summary
This prediction is currently active. The prediction currently has a performance of 24.95%. Dividends of €0.88 are taken into consideration when calculating the performance. This prediction currently runs until 27.08.26. The prediction end date can be changed by Sanford_C__Bernstein at any time. Sanford_C__Bernstein has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.399% | 2.399% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by Sanford_C__Bernstein for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Sanford_C__Bernstein for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
07.01.25
07.01.26
12.12.25
Regeneron Pharmaceuticals Inc.
12.03.24
12.03.25
13.03.25

